• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Computational Design Boosts Antibody Fragment Affinity for Meningococcal Protein

by
November 9, 2026
in Biology
Reading Time: 6 mins read
0
Computational Design Boosts Antibody Fragment Affinity for Meningococcal Protein

Computational Design Boosts Antibody Fragment Affinity for Meningococcal Protein

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Published in BMC Biotechnology in July 2026, the study details how molecular dynamics simulations were used to guide the selection of specific mutations, resulting in a variant with a significantly higher measured affinity than the native antibody fragment. The work highlights the growing utility of in silico approaches in the rational engineering of high-affinity binders for bacterial pathogens that have historically resisted traditional vaccine development.

The study focused on fHbp, a surface-exposed virulence determinant that plays a critical role in the pathogenesis of N. meningitidis. This protein mediates the primary interaction with human factor H, a regulatory protein of the complement system. By binding to factor H, fHbp downregulates the alternative complement pathway, thereby facilitating innate immune evasion and ensuring the survival of the bacteria in the human host. Because this interaction occurs on an extracellular and structurally accessible surface, fHbp represents an attractive target for antibody-based recognition and therapeutic intervention. The research team aimed to improve the binding strength of an existing scFv against this target to potentially enhance its utility in diagnostic or therapeutic applications.

The investigation began with the construction of a three-dimensional model of the parental scFv, which was selected in a previous study using ribosome display. The team utilized the PIGSpro server to generate this wild-type scFv model, leveraging canonical conformations to model the complementarity-determining region (CDR) loops with high precision. For the antigen, the researchers employed the crystal structure of fHbp, identified by PDB code 2KC0, which was resolved at a resolution of 2.86 Å. Molecular docking was then performed using the ClusPro server to identify the critical residues involved in the interaction between the scFv and fHbp. This docking analysis provided the structural basis for designing candidate mutations that could potentially strengthen the binding interface.

Guided by the docking results, the team designed approximately 300 single-point substitutions at scFv residues predicted to interact with fHbp. These mutations were evaluated based on several criteria, including spatial proximity to the interface, potential for hydrogen-bond formation, improved electrostatic complementarity, and steric compatibility. The resulting three-dimensional models of the variants were docked with fHbp, and the docking energy scores were used for primary screening. This process led to the prioritization of five specific variants for detailed analysis: Y35H, L31R, R99D, R99H, and A100K. All selected variants were located in the antibody VH chain, with the R99D mutation identified as a promising candidate due to its potential to introduce a beneficial charge reversal at the binding site.

To assess the structural stability of these candidates, the researchers performed all-atom molecular dynamics (MD) simulations using the GROMACS software package and the GROMOS96 43a1 force field. The simulations were conducted in a rhombic dodecahedral periodic simulation box filled with simple point-charge (SPC) water molecules and neutralized with Na⁺ and Cl⁻ counterions to achieve a final ionic strength of 150 mM, mimicking physiological conditions. The MD analyses identified five variants that exhibited markedly enhanced complex stability compared to the native form. In all variants, the scFv secondary structure remained intact, whereas fHbp showed shrinkage relative to the scFv in the V3 (R99D)–fHbp complexes during the simulations. Hydrogen-bonding patterns and inter-residue distances further supported the improved affinity of the variants relative to the native form.

The R99D variant showed the lowest root mean square deviation (RMSD) fluctuation and the lowest radius of gyration (Rg) fluctuation, suggesting superior structural consistency and conformational convergence within the fHbp–scFv complex. In contrast, other variants such as Y35H and R99H showed larger RMSD fluctuations, indicating that their mutations were less stable and required more time to equilibrate. The extended 50 ns simulation of the V3 (R99D) complex confirmed these findings, with RMSD values stabilizing at approximately 0.3–0.5 nm after initial equilibration, indicating excellent preservation of the overall complex structure and interface integrity.

To validate the computational predictions, the team recombinantly produced the V3 (R99D) scFv in Escherichia coli BL21(DE3) cells. Recombinant protein expression was induced with 1 mM IPTG, and the His-tagged protein was analyzed by SDS–PAGE and Western blotting. The purified scFv, which had a molecular weight of 27 kDa, was obtained using Ni²⁺-NTA agarose resin affinity chromatography. The purification process involved denaturing the cell pellets in 6 M urea, lysing by sonication, and eluting the protein with 500 mM imidazole. The final concentration of the purified scFv was determined to be 0.40 mg/mL, providing sufficient material for binding assays.

The binding affinity of the purified V3 (R99D) scFv for the recombinant fHbp antigen was determined using an ELISA-based method described by Beatty et al. An ELISA microplate was coated overnight with S-tagged fHbp antigen at various concentrations, and purified scFv antibodies were applied at serial dilutions. The experiments were performed with three independent biological replicates, with each condition tested in technical triplicate. The apparent affinity constant (Kaff) was calculated using the Beatty equation, which relates the ratio of antigen to antibody concentrations to the binding affinity.

The experimental results confirmed the computational predictions, revealing an affinity constant of 67.93 ± 0.02 × 10⁹ M⁻¹ for the V3 (R99D) scFv. This value represents a marked improvement over the native form of the scFv, which had a previously reported affinity of approximately 8.65 × 10⁹ M⁻¹. The increase in affinity suggests that the R99D mutation effectively enhanced the electrostatic complementarity and interfacial stability of the antibody-antigen complex. The study underscores the power of affinity maturation as a strategy for engineering high-affinity antibody fragments, particularly when guided by detailed structural simulations.

The authors noted that while docking scores and MD-derived stability descriptors are related to experimental affinity, they are not identical metrics. Docking scores were interpreted as qualitative ranking criteria rather than direct quantitative predictors of binding affinity, and MD parameters such as RMSD and Rg were used to assess structural stability rather than thermodynamic binding strength. The ELISA-based value reported in the study represents an apparent affinity measurement for the selected variant, rather than a full thermodynamic comparison of all designed mutants. The team acknowledged that future studies could benefit from more contemporary force fields and enhanced-sampling protocols to better capture infrequent conformational states and entropic contributions.

This study provides a streamlined and mechanistically coherent pathway for scFv affinity enhancement, bridging homology-based modeling, physics-based virtual screening, and empirical validation. The successful application of this workflow to N. meningitidis fHbp offers a compelling framework for accelerating the development of potent antibody fragments against high-priority bacterial pathogens. As in silico approaches become increasingly important in antibody engineering, such integrated strategies may facilitate the design of therapeutics against pathogens that have resisted traditional vaccine development, including bacteria and highly antigenically variable viruses.

The study situates its findings within a broader context of computational antibody engineering, noting that advances in antibody technology have enabled the design of optimized binders with greater speed and accuracy. The authors reference prior work in which in silico-guided affinity maturation was used to optimize antibody-like binders, including the redesign of nanobodies targeting the PLGF receptor and the rational engineering of affibody variants against HER2. In those examples, molecular dynamics simulations confirmed superior receptor engagement for specific charge-introduced mutants. Similar computational workflows have also been applied to refine bevacizumab for VEGF binding in ovarian cancer models and to generate stabilized scFv libraries against dengue envelope epitopes. More recently, such principles were extended to scFv mutants against small molecules like amantadine, where targeted substitutions produced a measurable increase in sensitivity.

Limitations of the current methodology are acknowledged in the discussion. The GROMOS96 43a1 force field and SPC water model adequately described short- to intermediate-timescale interface behavior, but the authors suggest that future studies may benefit from more contemporary parameter sets, such as CHARMM36m or AMBER ff19SB. Coupling these with enhanced-sampling protocols, such as Gaussian accelerated MD, could better capture infrequent conformational states and entropic contributions. Additionally, while ClusPro enabled efficient rigid-body sampling, integration with AI-augmented docking pipelines or AlphaFold3-generated conformational ensembles could improve pose discrimination and epitope specificity in subsequent optimization rounds.

The team also noted that additional model-quality validation using Ramachandran plot analysis, ERRAT, ProSA, or Verify3D would provide further confidence in the structural reliability of the designed variants. Complementary biophysical validation, such as isothermal titration calorimetry, is recommended to quantify the thermodynamic parameters underlying the scFv–fHbp interaction.

Subject of Research: Computational and experimental affinity maturation of an scFv antibody targeting Neisseria meningitidis factor H-binding protein

Article Title: Affinity improvement of specific scFvs interacting with the Neisseria meningitidis factor H-binding protein: a molecular dynamics simulation approach and experimental study

Article References: Ghazanfari, B., Ebrahimi, Z., Yarian, F., Lari, A., Ghanbariasad, A., & Kazemi, B. (2026). Affinity improvement of specific scFvs interacting with the Neisseria meningitidis factor H-binding protein: a molecular dynamics simulation approach and experimental study. BMC Biotechnology, 26(1), Article 122. https://doi.org/10.1186/s12896-026-01204-3

Image Credits: AI Generated

DOI: 10.1186/s12896-026-01204-3

Keywords: Neisseria meningitidis, factor H-binding protein, scFv, molecular dynamics, affinity maturation, antibody engineering, molecular docking, ELISA, protein engineering, BMC Biotechnology, Affinity, improvement

News Source: Gregory Coleman. (November 9, 2026). Computational Design Boosts Antibody Fragment Affinity for Meningococcal Protein. Scienmag.

Tags: affinityaffinity maturationantibody engineeringBMC BiotechnologyELISAfactor H-binding proteinimprovementmolecular dockingmolecular dynamicsNeisseria meningitidisProtein EngineeringscFv
Share12Tweet7Share2ShareShareShare1

Related Posts

Emerald Ash Borer Infestation Triggers Divergent Root Bacterial Shifts in Ash

Emerald Ash Borer Infestation Triggers Divergent Root Bacterial Shifts in Ash

November 16, 2026
Lespedeza cyrtobotrya Stem Extracts Inhibit Monoamine Oxidase Enzymes In Vitro

Lespedeza cyrtobotrya Stem Extracts Inhibit Monoamine Oxidase Enzymes In Vitro

November 16, 2026

Topical Endoret-Serum Enhances Collagen and Elastin in Preclinical Human Skin Models

November 16, 2026

BrCAMTA1 Gene Enhances Drought Resistance in Chinese Cabbage via Calcium Signaling

November 16, 2026

POPULAR NEWS

  • Emerald Ash Borer Infestation Triggers Divergent Root Bacterial Shifts in Ash

    Emerald Ash Borer Infestation Triggers Divergent Root Bacterial Shifts in Ash

    29 shares
    Share 12 Tweet 7
  • Lespedeza cyrtobotrya Stem Extracts Inhibit Monoamine Oxidase Enzymes In Vitro

    29 shares
    Share 12 Tweet 7
  • Sports Ethicists Urge Strict Limits on Performance Enhancing Swimming and Running Technologies

    29 shares
    Share 12 Tweet 7
  • Case Study Links Antipsychotic Drug Clozapine to Rare Colon Eosinophilic Cryptitis

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Emerald Ash Borer Infestation Triggers Divergent Root Bacterial Shifts in Ash

Lespedeza cyrtobotrya Stem Extracts Inhibit Monoamine Oxidase Enzymes In Vitro

Sports Ethicists Urge Strict Limits on Performance Enhancing Swimming and Running Technologies

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.